2,4,6-trivinylcycloboroxane pyridine complex | 95010-17-6

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 有机硼氧烷
• 英文名称: 2,4,6-trivinylcycloboroxane pyridine complex
• 英文别名: vinyl boronic anhydride pyridine complex；2,4,6-ethenylboroxin-pyridine；pyridine-triethenylboroxin；1-[2,4,6-Tris(ethenyl)-1,3,5-trioxa-4,6-dibora-2-boranuidacyclohex-2-yl]pyridin-1-ium；1-[2,4,6-tris(ethenyl)-1,3,5-trioxa-4,6-dibora-2-boranuidacyclohex-2-yl]pyridin-1-ium
• CAS: 95010-17-6
• 化学式: C₁₁H₁₄B₃NO₃
• 分子量: 240.67
• InChiKey: JDPWVNMRVRICEW-UHFFFAOYSA-N

物化性质

• 熔点：
  44 °C
• 沸点：
  78 °C
• 闪点：
  80 °C
• 溶解度：
  溶于甲醇。
• 稳定性/保质期：
  在常温常压下，该物质是稳定的，但对水较为敏感。

计算性质

• 辛醇/水分配系数(LogP)：
  0.98
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  31.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

制备方法与用途

用途

该产品广泛用于乙烯合成，在Suzuki-Miyaura交叉偶联反应条件下，可以与苯基卤化物反应生成高产率的苯乙烯衍生物。

反应信息

• 作为反应物：
  描述：

  2,4,6-trivinylcycloboroxane pyridine complex 、 3-溴异烟酸甲酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 cesium fluoride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以97%的产率得到methyl 3-vinyl-4-picolinate
  参考文献：
  名称：

  [EN] HETEROARYL INHIBITORS OF PAD4
  [FR] INHIBITEURS HÉTÉROARYLES DE PAD4

  摘要：

  本发明提供了作为PAD4抑制剂有用的化合物，其组成物，以及治疗PAD4相关疾病的方法。

  公开号：

  WO2017147102A1
• 作为产物：
  描述：

  吡啶 、 vinylboronic acid 以 乙醚 为溶剂， 反应 18.0h， 生成 2,4,6-trivinylcycloboroxane pyridine complex
  参考文献：
  名称：

  N-(4-substituted phenyl)-anthranilic acid hydroxamate esters

  摘要：

  本发明涉及氧化酯化的4-取代苯胺基苯基羟肟酸衍生物，以及其药物组合物和使用方法。

  公开号：

  US20040006245A1

文献信息

• [EN] ANTIBACTERIAL AGENTS<br/>[FR] AGENTS ANTIBACTERIENS
  申请人：GLAXO GROUP LTD

  公开号：WO2006014580A1

  公开（公告）日：2006-02-09

  Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

  萘、喹啉、喹喔啉和萘啉衍生物在哺乳动物，特别是人类的细菌感染治疗中是有用的。
• [EN] INHIBITORS OF AKT ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITÉ D'AKT
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010093885A1

  公开（公告）日：2010-08-19

  Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

  发明了新颖的杂环羧酰胺化合物，这些化合物可用作蛋白激酶B活性的抑制剂，并用于治疗癌症和关节炎。
• Tetrazine-Responsive Self-immolative Linkers
  作者：Kevin Neumann、Sarthak Jain、Alessia Gambardella、Sarah E. Walker、Elsa Valero、Annamaria Lilienkampf、Mark Bradley

  DOI：10.1002/cbic.201600560

  日期：2017.1.3

  Freed to kill: Doxorubicin was conjugated to PEG‐b‐Dox nanoparticles through a self‐immolative linker, comprised of a vinyl‐ether‐caged phenol that undergoes a 1,6‐elimination upon DAINV activation with tetrazine, thereby resulting in cargo release and switch‐on of cytotoxicity.

  释放自杀：阿霉素通过自消灭性连接体与PEG- b - Dox纳米颗粒结合，该连接体由乙烯基醚笼蔽的苯酚组成，在用四嗪激活DA INV后会被1,6消除，从而导致货物释放并开启细胞毒性作用。
• Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2–P1′ Region
  作者：Anna K. Lampa、Sara M. Bergman、Sofia S. Gustafsson、Hiba Alogheli、Eva B. Åkerblom、Gunnar G. Lindeberg、Richard M. Svensson、Per Artursson、U. Helena Danielson、Anders Karlén、Anja Sandström

  DOI：10.1021/ml400217r

  日期：2014.3.13

  Herein, novel hepatitis C virus NS3/4A protease inhibitors based on a P2 pyrimidinyloxyphenylglycine in combination with various regioisomers of an aryl acyl sulfonamide functionality in P1 are presented. The P1' 4-(trifluoromethyl)phenyl side chain was shown to be particularly beneficial in terms of inhibitory potency. Several inhibitors with K i-values in the nanomolar range were developed and included identification of promising P3-truncated inhibitors spanning from P2-P1'. Of several different P2 capping groups that were evaluated, a preference for the sterically congested Boc group was revealed. The inhibitors were found to retain inhibitory potencies for A156T, D168V, and R155K variants of the protease. Furthermore, in vitro pharmacokinetic profiling showed several beneficial effects on metabolic stability as well as on apparent intestinal permeability from both P3 truncation and the use of the P1' 4-(trifluoromethyl)phenyl side chain.
• Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents
  作者：Anna Lampa、Angelica E. Ehrenberg、Sofia S. Gustafsson、Aparna Vema、Eva Åkerblom、Gunnar Lindeberg、Anders Karlén、U. Helena Danielson、Anja Sandström

  DOI：10.1016/j.bmc.2010.05.027

  日期：2010.7

  Phenylglycine has proved to be a useful P2 residue in HCV NS3 protease inhibitors. A novel pi-pi-interaction between the phenylglycine and the catalytic H57 residue of the protease is postulated. We hypothesized that the introduction of a vinyl on the phenylglycine might strengthen this pi-pi-interaction. Thus, herein is presented the synthesis and inhibitory potency of a series of acyclic vinylated phenylglycine-based HCV NS3 protease inhibitors. Surprisingly, inhibitors based on both D-and L-phenylglycine were found to be effective inhibitors, with a slight preference for the D-epimers. Furthermore, prime-side alkenylic extension of the C-terminal acylsulfonamide group gave significantly improved inhibitors with potencies in the nanomolar range (similar to 35 nM), potencies which were retained on mutant variants of the protease. (C) 2010 Elsevier Ltd. All rights reserved.